SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Zohar_Power who wrote (2942)11/4/2013 2:40:52 PM
From: tom pope  Respond to of 4474
 
Good question. I'm beginning to think that one can't make an apples to apples comparison because apples change quiddity depending what basket they're in. At least in the FDA's eyes.



To: Zohar_Power who wrote (2942)11/4/2013 3:03:00 PM
From: Biomaven  Read Replies (2) | Respond to of 4474
 
Very likely Iclusig has a worse side-effect profile than Tasigna. As jq1234 has mentioned, Iclusig also hits VEGF, and that is known to bring some circulatory side effects with it. The Tasigna data is also pretty new - I would expect the FDA to address Tasigna with labeling changes.

What remains unclear is how many of the Iclusig SAE's were patients that were previously on Tasigna.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News